The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 2, 2015, Pages 186-195

  Sexton, Travis R ^a   Wallace, Eric L ^a   Macaulay, Tracy E ^a   Charnigo, Richard J ^a   Evangelista, Virgilio ^b   Campbell, Charles L ^a   Bailey, Alison L ^a   Smyth, Susan S ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; Platelets; Statin; Thromboinflammation

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CREATINE KINASE MB; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MYELOPEROXIDASE; NAP2 PROTEIN; PADGEM PROTEIN; PLACEBO; PRAVASTATIN; PURINERGIC P2Y12 RECEPTOR; RANTES; ROSUVASTATIN; SIMVASTATIN; THROMBOCYTE FACTOR 4; TROPONIN I; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXIDASE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME BLOOD LEVEL; FEMALE; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; BLOOD; CELL COMMUNICATION; DOSE RESPONSE; DRUG EFFECTS; EARLY INTERVENTION; MIDDLE AGED; PATHOPHYSIOLOGY; THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADULT; AGED; BIOMARKERS; BLOOD PLATELETS; CD40 LIGAND; CELL COMMUNICATION; CREATINE KINASE, MB FORM; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; P-SELECTIN; PEROXIDASE; PLATELET FACTOR 4; ROSUVASTATIN CALCIUM; THROMBOSIS; TREATMENT OUTCOME; TROPONIN I;

EID: 84925533328     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1142-x     Document Type: Article

References (24)

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124:e574–e651
2. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC (2009) Platelet functions beyond hemostasis. J Thromb Haemost 7:1759–1766
3. Kling D, Stucki C, Kronenberg S, Tuerck D, Rheaume E, Tardif JC, Gaudreault J, Schmitt C (2013) Pharmacological control of platelet–leukocyte interactions by the human anti-P-selectin antibody inclacumab–preclinical and clinical studies. Thromb Res 131:401–410
4. Tardif JC, Tanguay JF, Wright SS, Duchatelle V, Petroni T, Gregoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, L’Allier PL (2013) Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol 61:2048–2055
5. Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2007) Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 100:1659–1664
6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:1175–1182
7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504
8. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711–1718
9. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A (2009) Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 54:2157–2163
10. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G (2004) Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110:674–678
11. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49:1272–1278
12. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, Yoo NJ, Kim NH, Ahn YK, Jeong JW (2009) The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 137:246–251
13. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, Toy P, Werb Z, Looney MR (2012) Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 122:2661–2671
14. Maugeri N, Rovere-Querini P, Evangelista V, Godino C, Demetrio M, Baldini M, Figini F, Coppi G, Slavich M, Camera M, Bartorelli A, Marenzi G, Campana L, Baldissera E, Sabbadini MG, Cianflone D, Tremoli E, D’Angelo A, Manfredi AA, Maseri A (2012) An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS ONE 7:e39484
15. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A (2009) Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 54:558–565
16. Cay S, Cagirci G, Sen N, Balbay Y, Durmaz T, Aydogdu S (2010) Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther 24:41–47
17. Schafer A, Fraccarollo D, Eigenthaler M, Tas P, Firnschild A, Frantz S, Ertl G, Bauersachs J (2005) Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 25:1071–1077
18. van Oostrom AJ, Plokker HW, van Asbeck BS, Rabelink TJ, van Kessel KP, Jansen EH, Stehouwer CD, Cabezas MC (2006) Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis 185:331–339
19. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ (2002) Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol 22:1029–1035
20. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, Violi F (2005) Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111:412–419
21. Alber HF, Frick M, Suessenbacher A, Doerler J, Schirmer M, Stocker EM, Dichtl W, Pachinger O, Weidinger F (2006) Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease–a randomized, placebo-controlled study. Am Heart J 151:139
22. Patti G, Chello M, Pasceri V, Colonna D, Nusca A, Miglionico M, D’Ambrosio A, Covino E, Di Sciascio G (2006) Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 48:1560–1566
23. Ray KK, Cannon CP (2005) The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46:1425–1433
24. Weber C, Erl W, Weber KS, Weber PC (1997) HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30:1212–1217